Abstract 3594
Background
We conducted NGS of baseline UC tumors to elucidate molecular predictors of clinical outcomes on D/D+T.
Methods
CP1108/NCT01693562 was a nonrandomized phase I/II trial including 201 2L UC pts who were treated with D (10 mg/kg Q2W). Study 10/NCT02261220 was a phase I trial including 190 2L UC pts treated with D (20 mg/kg Q4W) +T (1 mg/kg Q4W). Pts with ≥25% PD-L1 expression in tumor or immune cells were scored as PD-L1+ by IHC. RNA-seq (n = 62) and whole exome sequencing (WES; n = 37) were used in CP1108. The IFN-γ gene signature (IFNGS) was calculated as described (Higgs B et al., 2018). TMB was calculated as somatic coding mutation count per mega base from WES data with TMB≥top tertile as TMB high. FMI assay (n = 62) was conducted in Study 10 with TMB≥top tertile as TMB high. ctDNA dynamics using Guardant360 were calculated using an established method (Raja R, et al., 2018). Wilcoxon, log-rank tests and COX-PH model were used in relevant statistical tests.
Results
Among ITT pts, 55% and 44.5% pts were PD-L1+ in CP1108 and Study 10 respectively. PD-L1 status correlated with IFNGS (p < 0.001), whereas PD-L1 did not correlate with TMB. PD-L1+ correlated with better OS in CP1108 (HR = 0.46, p < 0.001) but not in Study 10 (HR = 0.75, p = 0.2). IFNGS significantly correlated with better PFS in CP1108 (HR = 0.5, p = 0.02). Higher TMB in CP1108 using the median cutoff trended towards better OS (HR = 0.51, p = 0.18), but no clear trend using the top tertile cutoff due to small sample size. Higher TMB in Study 10 correlated with improved OS (HR = 0.34, p = 0.01). In Study 10, TMB and PD-L1 double positive pts (n = 14, 24%) had best OS and pts low in both had worst (n = 19, 32%, HR = 0.23, p = 0.01). Clearance of ctDNA after treatment correlated with better OS (HR = 0.23, p = 0.006) and PFS (HR = 0.33, p = 0.01) in combined UC pts from the 2 studies.
Conclusions
Both PD-L1 and TMB predict for survival benefit in UC pts treated with D/D+T. They identify overlapping but generally distinct patient populations. Double highs perform the best. ctDNA loss following treatment can be predictive for better survival.
Clinical trial identification
NCT01693562; NCT02261220.
Editorial acknowledgement
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
C. Massard: Advisory / Consultancy: Amgen; Advisory / Consultancy: Astellas; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Bayer; Advisory / Consultancy: Celgene; Advisory / Consultancy: Genentech; Advisory / Consultancy: Ipsen; Advisory / Consultancy: Novartis; Advisory / Consultancy: Roche; Speaker Bureau / Expert testimony: Sanofi; Advisory / Consultancy: Janssen; Advisory / Consultancy: Lilly; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Orion. H. Si: Full / Part-time employment: AstraZeneca. Q. Zhang: Full / Part-time employment: AstraZeneca. B. Higgs: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca. R. Raja: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca. S.E. Abdullah: Travel / Accommodation / Expenses, Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca. A. Gupta: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca; Shareholder / Stockholder / Stock options, Licensing / Royalties, Use of immunotherapy in the treatment of cancer-patent: Bristol-Myers Squibb. W. Li: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca. M. van der Heijden: Advisory / Consultancy: AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): BMS; Advisory / Consultancy: MSD; Advisory / Consultancy, Research grant / Funding (institution): Roche/Genentech; Advisory / Consultancy, Research grant / Funding (institution): Astellas; Advisory / Consultancy: Seattle Genetics.
Resources from the same session
4021 - Prospective pathological experience with research biopsies in the context of clinical trials at Vall d’Hebron Institute of Oncology
Presenter: Paolo Nuciforo
Session: Poster Display session 3
Resources:
Abstract
5603 - Development of a comprehensive next-generation targeted sequencing assay for detection of gene-fusions in solid tumors
Presenter: Vinay Mittal
Session: Poster Display session 3
Resources:
Abstract
4952 - Next-generation sequencing for better treatment strategy of cancer of unknown primary (CUP)
Presenter: Kang Kook Lee
Session: Poster Display session 3
Resources:
Abstract
4590 - Circulating-free DNA analysis from long-term surviving metastatic colorectal cancer patients undergoing surgery for resectable disease.
Presenter: Michele Ghidini
Session: Poster Display session 3
Resources:
Abstract
3696 - Ultra-sensitive detection of circulating tumor DNA identifies patients in high risk of recurrence in early stages melanoma
Presenter: Filip Janku
Session: Poster Display session 3
Resources:
Abstract
4295 - Identification of the founder BRCA1 mutation c.4117G>T (p.Glu1373*) recurring in Abruzzo and Lazio regions of Central Italy and predisposing to breast/ovarian and BRCA1-related cancers
Presenter: Daniela Di Giacomo
Session: Poster Display session 3
Resources:
Abstract
2214 - Enzalutamide (ENZA) and Apalutamide (APA) In vitro chemical reactivity studies and Activity in a Mouse Drug Allergy Model (MDAM)
Presenter: Mausumee Guha
Session: Poster Display session 3
Resources:
Abstract
5044 - Influence of genetic variation in COMT on cisplatin-induced nephrotoxicity in cancer patients.
Presenter: Bram Agema
Session: Poster Display session 3
Resources:
Abstract
3293 - Cardioprotective and anti-inflammatory effects of Empagliflozin during treatment with Doxorubicin: a cellular and preclinical study
Presenter: Vincenzo Quagliariello
Session: Poster Display session 3
Resources:
Abstract
3324 - Breast Cancer Organoids Model Treatment Response of HER2 Targeted Therapy in HER2-mutant Breast Cancer
Presenter: Xuelu Li
Session: Poster Display session 3
Resources:
Abstract